Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
John T. Lear(Salford Royal Hospital), Reinhard Dummer(University Hospital of Zurich), Karl D. Lewis(University of Colorado Denver), Ragini R. Kudchadkar, Alexander Guminski(The University of Sydney), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Uwe Trefzer(Goethe University Frankfurt), Manisha Mone, Anne Lynn S. Chang(Stanford University), Ruth Plummer(National Health Service), Dalila Sellami(Daiichi Sankyo (United States)), P. Combemale(Centre Léon Bérard), Luc Dirix(European Organisation for Research and Treatment of Cancer), Carmen Loquai(Johannes Gutenberg University Mainz), Tingting Yi(Army Medical University), Martin Kaatz(SRH Wald-Klinikum Gera), Henry Castro(CytomX Therapeutics (United States)), Alexander Stratigos(National and Kapodistrian University of Athens), J ZHOU(Novartis (United States)), Michael R. Migden(The University of Texas MD Anderson Cancer Center)
Cited by 192
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k